Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 10/20 | 0.46 |
| ▸ | PPARA | Q07869 | 7/20 | 0.46 |
| ▸ | PPARD | Q03181 | 6/20 | 0.44 |
| ▸ | ACLY | P53396 | 6/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
| ▸ | FLT4 | P35916 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3364943 | 0.90 | PPARG (0.49) | PPARGPPARAPPARDACLYFLT1 | |
| SCHEMBL3146521 | 0.83 | ACLY (0.50) | PPARGPPARAPPARDACLYFLT1 | |
| SCHEMBL3137788 | 0.80 | ACLY (0.63) | PPARGPPARAPPARDACLYFLT1 | |
| SCHEMBL3141535 | 0.77 | NOD2 (0.69) | PPARGPPARAPPARDACLYFLT1 | |
| SCHEMBL3362365 | 0.75 | HTR6 (0.42) | ACLYFLT1FLT4KDRMEN1 | |
| SCHEMBL3523012 | 0.75 | PPARG (0.76) | PPARGPPARAPPARD | |
| SCHEMBL3363385 | 0.75 | NOD2 (0.46) | PPARGPPARANOD2NOD1 | |
| SCHEMBL3136323 | 0.75 | PPARG (0.44) | PPARGPPARAPPARDACLYFLT1 | |
| SCHEMBL3528626 | 0.75 | PPARG (0.60) | PPARGPPARAPPARD | |
| SCHEMBL6964749 | 0.74 | CCR2 (0.52) | PPARGPPARAPPARDACLYFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118060-B1 | 1-BENZENESULFONYL-1H-INDOLE DERIVATIVES AS INHIBITORS OF CCR9 ACTIVITY | NOVARTIS AG (CH) | 2010-10-06 | — | — | EP | claimed |